Suvretta Capital Management LLC Sells 35,800 Shares of Sanofi (NASDAQ:SNY)

Suvretta Capital Management LLC decreased its position in shares of Sanofi (NASDAQ:SNY) by 17.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 174,901 shares of the company’s stock after selling 35,800 shares during the period. Suvretta Capital Management LLC’s holdings in Sanofi were worth $10,080,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after acquiring an additional 246,224 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after acquiring an additional 673,172 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Up 0.9 %

Shares of NASDAQ:SNY opened at $48.72 on Friday. The business has a 50-day moving average price of $53.17 and a 200-day moving average price of $52.15. The stock has a market cap of $123.64 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.23 and a beta of 0.61. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $2.55 EPS. Equities analysts predict that Sanofi will post 4.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.